Wednesday 22 July 2026

One To Watch

Immunitas Therapeutics

A clinical-stage precision immunotherapy company developing novel, differentiated therapeutics for patients with cancer.

Company Overview

Want to Update your Company's Profile?


Latest Immunitas Therapeutics News

Boehringer licenses antibody program from Immunitas
13 May 2026
Immunitas Therapeutics names Annalisa D’Andrea as CSO
18 January 2024
Immunitas Therapeutics launches with $39 million funding
21 November 2019
More Immunitas Therapeutics news >


Today's issue

Samsung Bioepis enters ADC license accord with IntoCell
Biotechnology
Samsung Bioepis enters ADC license accord with IntoCell
22 July 2026
Biosimilars
US House markup of expedited Access to Biosimilars Act welcomed
22 July 2026
Biotechnology
Sanofi publicly reprimanded after UK code breaches over Beyfortus promotion
21 July 2026
Pharmaceutical
Trial miss for Agios Pharma’s tebapivat in sickle cell disease
21 July 2026
Biotechnology
Lonza and Engitix join forces on targeted ADC development
21 July 2026
Pharmaceutical
Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns
21 July 2026
Biotechnology
EC expands Crysvita approval to infants with rare phosphate disorder
21 July 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze